3. GOOD HEALTH AND WELL-BEING

SVB Leerink Lowers agilon health (NYSE:AGL) Price Target to $30.00 – MarketBeat

Written by Amanda

SVB Leerink Lowers agilon health (NYSE:AGL) Price Target to $30.00  MarketBeat

agilon health (NYSE:AGLGet Rating) had its price target lowered by investment analysts at SVB Leerink from $33.00 to $30.00 in a research report issued on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. SVB Leerink’s target price would indicate a potential upside of 55.36% from the company’s current price.

AGL has been the subject of a number of other reports. TheStreet cut shares of agilon health from a “c-” rating to a “d+” rating in a research report on Thursday, August 18th. Royal Bank of Canada initiated coverage on shares of agilon health in a report on Wednesday, September 14th. They issued an “outperform” rating and a $33.00 price target on the stock. The Goldman Sachs Group started coverage on shares of agilon health in a research report on Monday, September 12th. They set a “buy” rating and a $38.00 price objective for the company. Truist Financial lowered their target price on agilon health from $33.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, September 7th. Finally, Wells Fargo & Company boosted their price target on agilon health from $23.00 to $28.00 and gave the company an “overweight” rating in a research note on Monday, August 8th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.57.

agilon health Stock Down 2.6 %

Shares of AGL stock opened at $19.31 on Friday. agilon health has a 52-week low of $14.36 and a 52-week high of $28.36. The stock has a market cap of $7.85 billion, a price-to-earnings ratio of -68.96 and a beta of 0.93. The firm’s 50-day moving average is $22.03 and its 200-day moving average is $21.78. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.65 and a current ratio of 2.65.

agilon health (NYSE:AGLGet Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). agilon health had a negative net margin of 4.99% and a negative return on equity of 9.80%. The business had revenue of $670.13 million during the quarter, compared to analyst estimates of $648.74 million. During the same period in the previous year, the business earned ($0.06) earnings per share. Sell-side analysts predict that agilon health will post -0.17 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Cd&R Investment Associates Ix, sold 11,337,500 shares of the stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $24.35, for a total transaction of $276,068,125.00. Following the sale, the insider now directly owns 194,611,308 shares of the company’s stock, valued at approximately $4,738,785,349.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other agilon health news, insider Benjamin Kornitzer sold 8,094 shares of the company’s stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $24.27, for a total transaction of $196,441.38. Following the completion of the sale, the insider now directly owns 10,426 shares in the company, valued at $253,039.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Cd&R Investment Associates Ix, sold 11,337,500 shares of the firm’s stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $24.35, for a total value of $276,068,125.00. Following the completion of the sale, the insider now directly owns 194,611,308 shares in the company, valued at approximately $4,738,785,349.80. The disclosure for this sale can be found here. Insiders have sold a total of 11,410,216 shares of company stock worth $277,646,991 in the last 90 days. Company insiders own 3.30% of the company’s stock.

Hedge Funds Weigh In On agilon health

Several large investors have recently modified their holdings of AGL. FMR LLC raised its position in agilon health by 14.9% during the 2nd quarter. FMR LLC now owns 34,862,287 shares of the company’s stock worth $761,043,000 after purchasing an additional 4,512,008 shares during the last quarter. Wellington Management Group LLP raised its position in shares of agilon health by 11.0% during the first quarter. Wellington Management Group LLP now owns 18,578,035 shares of the company’s stock worth $470,953,000 after acquiring an additional 1,834,890 shares during the last quarter. Capital Research Global Investors lifted its stake in shares of agilon health by 18.4% in the first quarter. Capital Research Global Investors now owns 9,867,875 shares of the company’s stock worth $250,151,000 after acquiring an additional 1,536,506 shares during the period. Swiss National Bank bought a new stake in agilon health in the second quarter valued at approximately $10,430,000. Finally, Capital World Investors increased its position in agilon health by 1.3% during the 1st quarter. Capital World Investors now owns 36,322,390 shares of the company’s stock valued at $920,773,000 after purchasing an additional 456,437 shares during the period.

agilon health Company Profile

(Get Rating)

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries.

Read More

Analyst Recommendations for agilon health (NYSE:AGL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider agilon health, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and agilon health wasn’t on the list.

While agilon health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: news.google.com

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment